You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

EGFR variant III

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Brain Cancer Trial in Basking Ridge, Commack, New York (erlotinib, Cytoreductive Surgery)

Completed
  • Brain Cancer
  • Basking Ridge, New Jersey
  • +3 more
Jan 6, 2021

Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive)

Recruiting
  • Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
  • +4 more
  • Cetuximab
  • +4 more
  • Los Angeles, California
    UCLA / Jonsson Comprehensive Cancer Center
Oct 4, 2021

Radiotherapy Combined With EGFR-TKI for Stage III EGFR Mutant

Completed
  • The Primary Study Metric is Progression-free Survival (PFS)
    • (no location specified)
    Jun 28, 2023

    Recurrent Glioblastoma Trial (Targeted Epidermal Growth Factor Receptor Variant III(EGFRvIII) autochimeric antigen receptor T

    Not yet recruiting
    • Recurrent Glioblastoma
    • Targeted Epidermal Growth Factor Receptor Variant III(EGFRvIII) autochimeric antigen receptor T cell injection
    • (no location specified)
    Apr 4, 2023

    Lung Cancer Stage III Trial (Almonertinib)

    Not yet recruiting
    • Lung Cancer Stage III
    • (no location specified)
    Aug 8, 2023

    NSCLC Trial (SKB264, Pemetrexed, Carboplatin)

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • (no location specified)
    May 23, 2023

    NSCLC, EGFR Sensitive Mutation, Adjuvant Therapy Trial in Beijing, Nanjing, Shanghai (Befotertinib + Icotinib , Icotinib +

    Recruiting
    • Non-Small Cell Lung Cancer
    • +2 more
    • Befotertinib + Icotinib placebo
    • Icotinib + Befotertinib placebo
    • Beijing, China
    • +2 more
    Sep 20, 2023

    Lung Adenocarcinoma Stage III, Lung Adenocarcinoma Stage IV, EGFR Gene Mutation Trial in Shanghai (Furmonertinib, Bevacizumab)

    Recruiting
    • Lung Adenocarcinoma Stage III
    • +2 more
    • Shanghai, Shanghai, China
      Shanghai Pulmonary Hospital
    Aug 13, 2022

    NSCLC Trial (PM8002, Placebo, Carboplatin)

    Not yet recruiting
    • NSCLC
    • (no location specified)
    Feb 23, 2023

    Lung Adenocarcinoma Stage III, EGFR Gene Mutation Trial in Shang'ai (Afatinib)

    Recruiting
    • Lung Adenocarcinoma Stage III
    • EGFR Gene Mutation
    • Shang'ai, Shanghai, China
      Shanghai Pulmonary Hospital
    Mar 27, 2022

    NSCLC Stage III, EGFR Positive NSCLC, Non-squamous Non-small-cell Lung Cancer Trial in Korea, Republic of (Lazertinib)

    Recruiting
    • Non-small Cell Lung Cancer Stage III
    • +2 more
    • Busan, Korea, Republic of
    • +12 more
    Jan 17, 2023

    NSCLC Trial in Shanghai (SH-1028 tablets, Placebo SH-1028 tablets)

    Recruiting
    • Non-small Cell Lung Cancer
    • SH-1028 tablets
    • Placebo SH-1028 tablets
    • Shanghai, Shanghai, China
      Shanghai Pulmonary Hospital
    Oct 6, 2023

    Lung Adenocarcinoma Stage III Trial in Shanghai (HS-10296 (Almonertinib))

    Recruiting
    • Lung Adenocarcinoma Stage III
    • HS-10296 (Almonertinib)
    • Shanghai, Shanghai, China
      Shanghai Pulmonary Hospital
    Mar 17, 2022

    NSCLC Metastatic Trial in Shanghai (Almonertinib, SBRT)

    Recruiting
    • Non-small Cell Lung Cancer Metastatic
    • Shanghai, Shanghai, China
      Fudan University Shanghai Cancer Center
    Mar 23, 2023

    NSCLC Trial (Idylla EGFR_IUO/3.20 Mutation Test)

    Not yet recruiting
    • NSCLC
    • Idylla EGFR_IUO/3.20 Mutation Test
    • (no location specified)
    Jul 24, 2023

    Gastric or Esophagogastric Junction Adenocarcinoma Trial (nimotuzumab plus paclitaxel, plus paclitaxel)

    Not yet recruiting
    • Gastric or Esophagogastric Junction Adenocarcinoma
    • nimotuzumab plus paclitaxel
    • placebo plus paclitaxel
    • (no location specified)
    Aug 3, 2023

    Non-Squamous NSCLC Trial in Guangzhou (AK112 Injection, Placebo Injection)

    Recruiting
    • Non-Squamous Non-small Cell Lung Cancer
    • AK112 Injection
    • Placebo Injection
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Center
    May 23, 2022

    NSCLC Trial in Japan, Korea, Republic of, Singapore (capmatinib, pemetrexed, cisplatin)

    Terminated
    • Carcinoma, Non-Small-Cell Lung
    • Kashiwa, Chiba, Japan
    • +3 more
    Jan 31, 2023

    Non-Squamous NSCLC Trial in Shanghai (Sintilimab, IBI305, Pemetrexed)

    Recruiting
    • Non-Squamous Non-Small Cell Lung Cancer
    • Shanghai, Shanghai, China
      Shanghai Chest Hospital
    Sep 22, 2022

    Glioblastoma Trial in Worldwide (RO7428731)

    Recruiting
    • Glioblastoma
    • Melbourne, Victoria, Australia
    • +4 more
    Aug 2, 2022

    NSCLC, EGFR Activating Mutation Trial in Changsha, Shanghai (TY-9591, Osimertinib, Osimertinib)

    Recruiting
    • NSCLC
    • EGFR Activating Mutation
    • Changsha, Hunan, China
    • +1 more
    Dec 6, 2022

    Hydronephrosis, Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant, Infiltrating Bladder Urothelial Carcinoma,

    Active, not recruiting
    • Hydronephrosis
    • +18 more
    • Durvalumab
    • +2 more
    • Houston, Texas
      M D Anderson Cancer Center
    Oct 31, 2022

    Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7

    Active, not recruiting
    • Metastatic Lung Non-Small Cell Carcinoma
    • +5 more
    • Laboratory Biomarker Analysis
    • +3 more
    • New Haven, Connecticut
    • +4 more
    Jan 27, 2023

    NSCLC, Brain Metastases, EGFR Mutation Trial in Guangzhou (Gefitinib and Pemetrexed/platinum, Gefitinib mono-therapy)

    Recruiting
    • Non-small Cell Lung Cancer
    • +2 more
    • Gefitinib and Pemetrexed/platinum
    • Gefitinib mono-therapy
    • Guangzhou, Guangdong, China
      Sun Yat-sen University of Cancer Center
    Feb 19, 2022

    Bladder Squamous Cell Carcinoma, Locally Advanced Bladder Carcinoma, Malignant Renal Pelvis Tumor Trial in Atlanta (procedure,

    Not yet recruiting
    • Bladder Squamous Cell Carcinoma
    • +10 more
    • Biospecimen Collection
    • +5 more
    • Atlanta, Georgia
    • +3 more
    Feb 20, 2023